Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 20,645 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director John Schmid sold 20,645 shares of the firm’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $56.11, for a total value of $1,158,390.95. Following the sale, the director directly owned 31,622 shares of the company’s stock, valued at $1,774,310.42. This trade represents a 39.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

AnaptysBio Price Performance

NASDAQ:ANAB traded up $2.78 during mid-day trading on Thursday, reaching $59.51. The stock had a trading volume of 73,440 shares, compared to its average volume of 547,658. The stock has a market cap of $1.71 billion, a P/E ratio of -114.72 and a beta of 0.40. The business’s 50 day moving average is $55.88 and its 200 day moving average is $44.33. AnaptysBio, Inc. has a fifty-two week low of $15.40 and a fifty-two week high of $68.39.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.89 by $0.69. The company had revenue of $108.25 million for the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. Equities analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its board has approved a stock buyback program on Friday, March 27th that allows the company to buyback $100,000.00 billion in outstanding shares. This buyback authorization allows the biotechnology company to repurchase up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

ANAB has been the subject of several recent analyst reports. Wall Street Zen downgraded AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Wedbush boosted their target price on AnaptysBio from $60.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, January 21st. Finally, Stifel Nicolaus increased their price target on AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $80.10.

Institutional Investors Weigh In On AnaptysBio

Hedge funds have recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its stake in shares of AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the period. Larson Financial Group LLC boosted its position in shares of AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in AnaptysBio by 24.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 263 shares during the period. Bessemer Group Inc. raised its stake in AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in AnaptysBio by 940.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 1,383 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.